Stealth BioTherapeutics Profit Margin 2018-2021 | MITO

Current and historical gross margin, operating margin and net profit margin for Stealth BioTherapeutics (MITO) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Stealth BioTherapeutics net profit margin as of June 30, 2021 is 0%.
Stealth BioTherapeutics Annual Profit Margins
Stealth BioTherapeutics Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.081B $0.021B
Stealth BioTherapeutics Corp is a biopharmaceutical company. It is engaged in developing therapies to treat the mitochondrial dysfunction associated with genetic mitochondrial diseases and many common age-related diseases. The company's product pipeline includes Elamipretide, SBT-20 and SBT-272 which are in clinical stage. Stealth BioTherapeutics Corp is based in Newton, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00